1. Home
  2. NWSA vs BIIB Comparison

NWSA vs BIIB Comparison

Compare NWSA & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NWSA
  • BIIB
  • Stock Information
  • Founded
  • NWSA 2012
  • BIIB 1978
  • Country
  • NWSA United States
  • BIIB United States
  • Employees
  • NWSA N/A
  • BIIB N/A
  • Industry
  • NWSA Newspapers/Magazines
  • BIIB Biotechnology: Pharmaceutical Preparations
  • Sector
  • NWSA Consumer Discretionary
  • BIIB Health Care
  • Exchange
  • NWSA Nasdaq
  • BIIB Nasdaq
  • Market Cap
  • NWSA 14.9B
  • BIIB 18.7B
  • IPO Year
  • NWSA N/A
  • BIIB 1991
  • Fundamental
  • Price
  • NWSA $26.50
  • BIIB $152.47
  • Analyst Decision
  • NWSA Strong Buy
  • BIIB Buy
  • Analyst Count
  • NWSA 7
  • BIIB 24
  • Target Price
  • NWSA $38.28
  • BIIB $174.62
  • AVG Volume (30 Days)
  • NWSA 3.4M
  • BIIB 1.6M
  • Earning Date
  • NWSA 11-06-2025
  • BIIB 10-30-2025
  • Dividend Yield
  • NWSA 0.80%
  • BIIB N/A
  • EPS Growth
  • NWSA 345.01
  • BIIB N/A
  • EPS
  • NWSA 2.07
  • BIIB 10.97
  • Revenue
  • NWSA $8,452,000,000.00
  • BIIB $10,065,900,000.00
  • Revenue This Year
  • NWSA $4.66
  • BIIB $2.97
  • Revenue Next Year
  • NWSA $3.48
  • BIIB N/A
  • P/E Ratio
  • NWSA $12.13
  • BIIB $14.28
  • Revenue Growth
  • NWSA 2.42
  • BIIB 4.77
  • 52 Week Low
  • NWSA $23.38
  • BIIB $110.04
  • 52 Week High
  • NWSA $31.61
  • BIIB $179.20
  • Technical
  • Relative Strength Index (RSI)
  • NWSA 47.96
  • BIIB 56.05
  • Support Level
  • NWSA $25.77
  • BIIB $148.90
  • Resistance Level
  • NWSA $26.57
  • BIIB $157.79
  • Average True Range (ATR)
  • NWSA 0.56
  • BIIB 4.78
  • MACD
  • NWSA 0.07
  • BIIB 0.32
  • Stochastic Oscillator
  • NWSA 80.14
  • BIIB 73.67

About NWSA News Corporation

News Corporation is a diversified media conglomerate with large presence in the US, the UK, and Australia. Key mastheads include The Wall Street Journal, Barron's, New York Post, The Times, The Sun, The Australian, Herald Sun, and The Daily Telegraph. Its 61%-owned REA Group is the dominant property listings business in Australia. In addition, it owns Harper Collins, one of the largest book publishers in the world, and has a sizable US digital property advertising business, Move. The 65% interest in Foxtel, the Australian pay-TV and streaming provider, was sold in April 2025. The sale to global sports streaming platform, DAZN, was struck at more than 7 times Foxtel's EBITDA.

About BIIB Biogen Inc.

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Share on Social Networks: